Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Haematologica|September 2, 2017
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myelomaSusana Hernández-García, Laura San-Segundo, Lorena González-Méndez, et al.
Blood|September 28, 2013
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profileBruno Paiva, Teresa Paino, Jose-Maria Sayagues, et al.
Haematologica|June 13, 2015
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trialRamón García-Sanz, Albert Oriol, María J Moreno, et al.
Blood|January 27, 2011
The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosisBruno Paiva, María-Belén Vídriales, José J Pérez, et al.
Annals of Hematology|June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myelomaIvan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
British Journal of Haematology|June 6, 2020
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM groupEnrique M Ocio, Cristina Motlló, Paula Rodríguez-Otero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2014
Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone diseaseAntonio Garcia-Gomez, Dalia Quwaider, Miriam Canavese, et al.
Leukemia|June 14, 2023
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantationEnrique M Ocio, Aurore Perrot, Pierre Bories, et al.
Cancers|December 8, 2020
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical TrialNoemí Puig, Luis A Corchete-Sánchez, José J Pérez-Morán, et al.
Transplantation and Cellular Therapy|July 9, 2026
FEASIBILITY AND INTERIM SAFETY AND EFFICACY ANALYSIS OF A FAST AUTOMATED PRODUCTION OF PROPHYLACTIC CMV-SPECIFIC CTLs AFTER ALLOGENEIC HSCTMa Aránzazu Bermúdez, Oscar M Pello, Miriam Sánchez-Escamilla, et al.
Pageof 13